NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

成人史迪爾氏病 (AOSD) - 市場考察,流行病學,市場預測:2030年

Adult-onset Still's Disease Market Insights, Epidemiology, and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 973321
出版日期 按訂單生產 內容資訊 英文 131 Pages
商品交期: 10個工作天內
價格
成人史迪爾氏病 (AOSD) - 市場考察,流行病學,市場預測:2030年 Adult-onset Still's Disease Market Insights, Epidemiology, and Market Forecast - 2030
出版日期: 按訂單生產內容資訊: 英文 131 Pages
簡介

2017年,七個主要市場的成人靜止性疾病(AOSD)總流行率為13,191。據估計,美國的人數最多,2017年為3,970人。

本報告提供成人史迪爾氏病 (AOSD) 調查分析,以過去·未來的流行病學,美國·歐洲5個國家 (德國,西班牙,義大利,法國,英國) ·日本的市場趨勢為焦點,提供目前治療方法,新藥,市場規模等相關的系統性資訊。

目錄

第1章 主要考察

第2章 成人史迪爾氏病 (AOSD)的摘要整理

第3章 成人史迪爾氏病 (AOSD)的市場概要

  • 2017年的成人史迪爾氏病 (AOSD)的市場佔有率分佈
  • 2030年的成人史迪爾氏病 (AOSD)的市場佔有率分佈

第4章 概要與背景

  • 簡介
  • 病因
  • 歷史和物理
  • 症狀
  • 病因
  • 臨床症狀
  • 成人史迪爾氏病 (AOSD) 生物標記
  • 診斷

第5章 流行病學和患者族群

  • 主要調查結果

第6章 主要7個國家的流行病學

  • 前提條件與理論的根據
  • 主要7個國家的成人史迪爾氏病 (AOSD)的整體患病人數
  • 美國
  • 歐洲5個國家
  • 日本

第7章 治療

第8章 未滿足需求

第9章 對成人史迪爾氏病 (AOSD) 有貢獻的組織

第10章 案例研究

第11章 KOL的見解

第12章 患者療程

第13章 上市藥

第14章 新藥

第15章 其他有力藥

第16章 市場分析成人史迪爾氏病 (AOSD) :主要7個國家

  • 主要調查結果
  • 主要7個國家的成人史迪爾氏病 (AOSD)的市場規模

第17章 市場預測主要7個國家

第18章 推動市場要素

第19章 市場障礙

第20章 成人史迪爾氏病 (AOSD)的SWOT分析

第21章 償付

第22章 附錄

第23章 DelveInsight的服務內容

第24章 免責聲明

第25章 關於DelveInsight

目錄

DelveInsight's "Adult-onset Still's Disease Market Insights, Epidemiology, and Market Forecast - 2030" report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the market trends of adult-onset Still's disease in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The adult-onset Still's disease (AOSD) market report provides analysis regarding current treatment practices, emerging drug-like CERC-007 (Cerecor) and potential therapies, market share of the individual therapies, historical, current, and forecasted adult-onset Still's disease market size from 2017 to 2030, segmented by seven major markets.

The report also covers current adult-onset Still's disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assess the market's underlying potential.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Adult-onset Still's Disease- Disease Understanding and Treatment Algorithm

Adult-onset Still's Disease Overview

Adult-onset Still's Disease (AOSD) is a rare type of arthritis thought to be autoimmune or autoinflammatory. It has similar symptoms to systemic-onset juvenile idiopathic arthritis - fever, rash, and joint pain. It begins in adulthood, so it is compared to rheumatoid arthritis. Inflammation may affect a few joints at first. Over time, more joints may be involved. Some people may have only one bout of the illness followed by lasting remission (no visible symptoms), while others develop chronic arthritis.

In adult-onset Still's disease, symptoms typically come and go in episodes. For some, these go on for about a year, and then the disease goes away. For others, the episodes come on at random, going away for weeks or months and then coming back. The patient may also have chronic AOSD, where the symptoms are more constant than others. The initial indications are high fever and pink rash.

Diagnosing AOSD is difficult because there are no specific tests or distinguishing laboratory (histopathologic) findings that differentiate the disorder from similar disorders. A diagnosis of AOSD is usually made based upon thorough clinical evaluation, a detailed patient history, identification of characteristic findings, and the exclusion of other possible disorders (diagnosis of exclusion). A variety of tests may be performed to aid in the diagnosis, including blood tests and x-ray studies that reveal changes in the bones or joints or enlargement of the spleen or liver. An echocardiogram, which uses sound waves to create a picture of the heart, may reveal inflammation of the pericardium or myocardium.

Adult-onset Still's Disease Treatment

This chapter covers the details of conventional and current medical therapies available in the adult-onset Still's disease market to treat the condition. It also provides the country-wise adult-onset Still's disease treatment guidelines across the United States, Europe, and Japan.

DelveInsight's adult-onset Still's disease market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides adult-onset Still's disease treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Currently, the treatment of AOSD patients remains empirical. The disease's clinical course is variable and ranges from self-limiting clinical forms to life-threatening complications; thus, the best therapy has not yet been defined and still counts on personal clinical experiences. The ongoing predominant clinical features (systemic or articular) and the presence/absence of complications must be considered to identify the appropriate individualized strategy factors determining the disease phase (onset, maintenance, flares).

The treatment of AOSD is centered on nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, and antirheumatic agents.

Adult-onset Still's Disease Epidemiology

The adult-onset Still's disease epidemiology chapters provide insights about historical and current adult-onset Still's disease patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Adult-onset Still's Disease epidemiology is segmented by total prevalent cases, gender-specific cases, and complications-associated with AOSD. The report includes a thorough analysis of all segmentations.

According to DelveInsight's estimate, the total prevalent cases of adult-onset Still's disease in the 7MM countries was 13,191 in 2017. As per the estimates, the United States had the highest prevalent population of adult-onset Still's disease with 3,970 cases in 2017

Adult-onset Still's Disease Drug Chapters

The drug chapter segment of the Adult-onset Still's Disease report encloses the detailed analysis of Adult-onset Still's Disease pipeline drug. It also helps understand the Adult-onset Still's Disease clinical trial details, expressive pharmacological action, the included drug's agreements, and the latest news and press releases.

To date, the use of medications in adult-onset Still's disease has been considered controversial. Many treatments discussed in this section remain investigational. Canakinumab (INN), sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis (SJIA) and active Still's disease, including AOSD. It is a human monoclonal antibody targeted at interleukin-1 beta and has no cross-reactivity with other interleukin-1 family members, including interleukin-1 alpha. Ilaris works by blocking the action of IL-1 beta for a sustained period, therefore inhibiting inflammation caused by its over-production. Apart from these, many drugs are still under trials or need more proper studies to prove efficacy. Thus, any significant development in this direction is expected to create a tectonic impact on the existing market scenario during our forecast period.

Adult-onset Still's Disease Market Outlook

The adult-onset Still's disease market size is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest adult-onset Still's disease market size, with USD 14.3 million, while Japan's AOSD market size was USD 8.5 million in 2017.

Adult-onset Still's Disease Drugs Uptake

This section focuses on the uptake of the potential drugs in the adult-onset Still's disease market expected to get launched in the market during the study period 2017-2030. The analysis covers adult-onset Still's disease market uptake by drugs, patient uptake by therapies, and drug sale.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and comparison of the drugs based on market share and size, which will again be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The dynamics of the adult-onset Still's disease market is anticipated to experience a positive shift in the coming years due to the expected launch of emerging therapies.

Adult-onset Still's Disease Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses adult-onset Still's disease key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers adult-onset Still's disease collaborations, acquisition and merger, licensing, patent details, and other information for Adult-onset Still's Disease emerging therapies.

Reimbursement Scenario in Alcoholic Hepatitis

Proactively approaching reimbursement can positively impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in the Adult-onset Still's Disease domain through primary research to fill the data gaps and validate our secondary research. This will support the clients in potential upcoming novel treatment by identifying the market's overall scenario and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Adult-onset Still's Disease Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, and Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Highlights:

  • In the coming years, the Adult-onset Still's Disease market scenario is expected to alter across the 7MM due to the launch of a few therapies covering the drawbacks of the standard of care.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Adult-onset Still's Disease Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Adult-onset Still's Disease Pipeline Analysis
  • Adult-onset Still's Disease Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Adult-onset Still's Disease Report Key Strengths

  • 11-years Forecast
  • 7MM Coverage
  • Adult-onset Still's Disease Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Adult-onset Still's Disease Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the adult-onset Still's disease market share (%) distribution in 2017, and how it would look like in 2030?
  • What would be the adult-onset Still's disease total market size and market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest adult-onset Still's disease market size during the forecast period (2017-2030)?
  • At what CAGR, adult-onset Still's disease market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the adult-onset Still's disease market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the adult-onset Still's disease market growth until 2030, and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risks, burdens, and unmet needs of adult-onset Still's disease?
  • What is the historical adult-onset Still's disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of adult-onset Still's disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to adult-onset Still's disease?
  • Out of all 7MM countries, which country would have the highest prevalent population of adult-onset Still's disease during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for adult-onset Still's disease treatment, along with the approved therapy?
  • What are the current treatment guidelines for treating adult-onset Still's disease in the USA, Europe, and Japan?
  • What is the adult-onset Still's disease marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of adult-onset Still's disease?
  • How many therapies are developed by each company for adult-onset Still's disease treatment?
  • How many are emerging therapies in mid-stage and late-stage of development for adult-onset Still's disease treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the adult-onset Still's disease therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for adult-onset Still's disease and their status?
  • What are the key designations that have been granted for the emerging therapies for adult-onset Still's disease?
  • What are the global historical and forecasted market of adult-onset Still's disease?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the adult-onset Still's disease market
  • To understand the future market competition in the adult-onset Still's disease market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for adult-onset Still's disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the adult-onset Still's disease market
  • To understand the future market competition in the adult-onset Still's disease market
  • Which geography accounted for the largest adult-onset Still's disease market size?
  • The United States accounted for the largest adult-onset Still's disease market size.
  • What is the forecasted adult-onset Still's disease market size in 2030?
  • DelveInsight estimates an increase in adult-onset Still's disease Market Size during the study period, 2017-2030
  • What is the present adult-onset Still's disease market drivers?
  • The novel treatment options and diagnostic biomarkers are likely to drive the AOSD market.
  • What is adult-onset Still's disease market barriers?
  • Key barriers to drug development include research limitation, lack of etiology, and specific diagnosis.
  • How many companies are developing drugs for adult-onset Still's disease?
  • Cerecor is working robustly in providing effective treatment to individuals suffering from AOSD.
  • Which are the leading companies in the adult-onset Still's disease market?

Cerecor.

How is epidemiology segmented for adult-onset Still's disease?

It is segmented into the total prevalent cases, gender-specific cases of AOSD, and complications associated with AOSD.

Table of Contents

1 Key Insights

2 Executive Summary of AOSD

3 Adult-onset Still's Disease Market Overview at a Glance

  • 3.1 Market Share (%) Distribution of Adult-onset Still's Disease in 2017
  • 3.2 Market Share (%) Distribution of Adult-onset Still's Disease in 2030

4 Overview and Background

  • 4.1 Introduction
  • 4.2 Etiology
  • 4.3 History and Physical
  • 4.4 Symptoms
  • 4.5 Pathogenesis
  • 4.6 Clinical Manifestation
  • 4.7 AOSD biomarkers
  • 4.8 Diagnosis
    • 4.8.1 Diagnostic criteria for AOSD

5 Epidemiology and Patient Population

  • 5.1 Key Findings

6 7MM Epidemiology

  • 6.1 Assumptions and rationale
  • 6.2 Total Prevalent Cases of Adult-onset Still's Disease (AOSD) in 7MM
  • 6.3 The United States
    • 6.3.1 Total Prevalent cases of Adult-onset Still's Disease (AOSD) in the United States
    • 6.3.2 Gender-Specific cases of Adult-onset Still's Disease (AOSD) in the United States
    • 6.3.3 Complications Associated with Adult-onset Still's Disease (AOSD) in the United States
  • 6.4 EU5 Countries
    • 6.4.1 Germany
    • 6.4.2 France
    • 6.4.3 Italy
    • 6.4.4 Spain
    • 6.4.5 United Kingdom
  • 6.5 Japan

7 Treatment

8 Unmet Needs

9 Organizations contributing toward AOSD

10 Case Study

  • 10.1 Adult-onset Still's disease initially thought to be an odontogenic infection: A case report
  • 10.2 Adult-onset Still's Disease Complicated by Autoimmune Hepatitis: Successful Treatment with Infliximab
  • 10.3 Complex presentation of adult-onset Still's disease
  • 10.4 A complete response to steroids in dural inflammatory pseudotumor associated with Still's disease

11 KOL Views

12 Patient Journey

13 Marketed Therapies

  • 13.1 Canakinumab: Novartis
    • 13.1.1 Drug Description
    • 13.1.2 Other Development Activities
    • 13.1.3 Clinical Development
    • 13.1.4 Safety and Efficacy
  • 13.2 Anakinra: Swedish Orphan Biovitrum
    • 13.2.1 Drug Description
    • 13.2.2 Other Development Activities
    • 13.2.3 Clinical Development
    • 13.2.4 Safety and Efficacy
  • 13.3 Tocilizumab: Roche
    • 13.3.1 Drug Description
    • 13.3.2 Other Development Activities
    • 13.3.3 Clinical Development
    • 13.3.4 Safety and Efficacy

14 Emerging Therapies

  • 14.1 CERC-007: Cerecor
    • 14.1.1 Drug Description
    • 14.1.2 Other Development Activities
    • 14.1.3 Safety and Efficacy

15 Other Promising Therapies

  • 15.1 Tadekinig Alfa: AB2 Bio Ltd
    • 15.1.1 Drug Description
    • 15.1.2 Other Development Activities
    • 15.1.3 Clinical Development
    • 15.1.4 Safety and Efficacy

16 Adult-onset Still's Disease (AOSD): 7 Major Market Analysis

  • 16.1 Key Findings
  • 16.2 Market Size of Adult-onset Still's Disease (AOSD) in 7MM

17 Seven Major Market Outlook

  • 17.1 The United States Market Size
    • 17.1.1 Total Market Size of Adult-onset Still's Disease (AOSD) in the United States
    • 17.1.2 Total Market Size of Adult-onset Still's Disease (AOSD) by Therapies in the United States
  • 17.2 Germany
    • 17.2.1 The total market size of Adult-onset Still's Disease (AOSD) in Germany
    • 17.2.2 Market size of Adult-onset Still's Disease (AOSD) by Therapies in Germany
  • 17.3 France
    • 17.3.1 The total market size of Adult-onset Still's Disease (AOSD) in France
    • 17.3.2 Market size of Adult-onset Still's Disease (AOSD) by Therapies in France
  • 17.4 Italy
    • 17.4.1 The total market size of Adult-onset Still's Disease (AOSD) in Italy
    • 17.4.2 Market size of Adult-onset Still's Disease (AOSD) by Therapies in Italy
  • 17.5 Spain
    • 17.5.1 Total Market Size of Adult-onset Still's Disease (AOSD) in Spain
    • 17.5.2 Market size of Adult-onset Still's Disease (AOSD) by Therapies in Spain
  • 17.6 United Kingdom
    • 17.6.1 The total market size of Adult-onset Still's Disease (AOSD) in the United Kingdom
    • 17.6.2 Market size of Adult-onset Still's Disease (AOSD) by Therapies in the UK
  • 17.7 Japan
    • 17.7.1 The total market size of Adult-onset Still's Disease (AOSD) in Japan
    • 17.7.2 Market size of Adult-onset Still's Disease (AOSD) by Therapies in Japan

18 Market Drivers

19 Market Barriers

20 SWOT Analysis for AOSD

21 Reimbursement

22 Appendix

  • 22.1 Report Methodology
  • 22.2 References

23 DelveInsight Capabilities

24 Disclaimer

25 About DelveInsight

List of Tables

  • Table 1: Summary of Adult-onset Still's Disease Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Serum biomarkers in AOSD
  • Table 3: Total Prevalent Cases of Adult-onset Still's Disease (AOSD) in 7MM (2017-2030)
  • Table 4: Total Prevalent cases of Adult-onset Still's Disease (AOSD) in the United States (2017-2030)
  • Table 5: Gender-specific cases of Adult-onset Still's Disease (AOSD) in the US (2017-2030)
  • Table 6: Complications Associated with Adult-onset Still's Disease (AOSD) in the US (2017-2030)
  • Table 7: Total Prevalent cases of Adult-onset Still's Disease (AOSD) in Germany (2017-2030)
  • Table 8: Gender-specific cases of Adult-onset Still's Disease (AOSD) in Germany (2017-2030)
  • Table 9: Complications Associated with Adult-onset Still's Disease (AOSD) in Germany (2017-2030)
  • Table 10: Total Prevalent cases of Adult-onset Still's Disease (AOSD) in France (2017-2030)
  • Table 11: Gender-specific cases of Adult-onset Still's Disease (AOSD) in France (2017-2030)
  • Table 12: Complications Associated with Adult-onset Still's Disease (AOSD) in France (2017-2030)
  • Table 13: Total Prevalent cases of Adult-onset Still's Disease (AOSD) in Italy (2017-2030)
  • Table 14: Gender-specific cases of Adult-onset Still's Disease (AOSD) in Italy (2017-2030)
  • Table 15: Complications Associated with Adult-onset Still's Disease (AOSD) in Italy (2017-2030)
  • Table 16: Total Prevalent cases of Adult-onset Still's Disease (AOSD) in Spain (2017-2030)
  • Table 17: Gender-specific cases of Adult-onset Still's Disease (AOSD) in Spain (2017-2030)
  • Table 18: Complications Associated with Adult-onset Still's Disease (AOSD) in the US (2017-2030)
  • Table 19: Total Prevalent cases of Adult-onset Still's Disease (AOSD) in the United Kingdom (2017-2030)
  • Table 20: Gender-specific cases of Adult-onset Still's Disease (AOSD) in the UK (2017-2030)
  • Table 21: Complications Associated with Adult-onset Still's Disease (AOSD) in the UK (2017-2030)
  • Table 22: Total Prevalent cases of Adult-onset Still's Disease (AOSD) in Japan (2017-2030)
  • Table 23: Gender-specific cases of Adult-onset Still's Disease (AOSD) in Japan (2017-2030)
  • Table 24: Complications Associated with Adult-onset Still's Disease (AOSD) in the UK (2017-2030)
  • Table 25: Canakinumab, Product Description
  • Table 26: Canakinumab, Clinical Trial Description, 2020
  • Table 27: Anakinra, Product Description
  • Table 28: Anakinra, Clinical Trial Description, 2020
  • Table 29: Tocilizumab, Product Description
  • Table 30: Tocilizumab, Clinical Trial Description, 2020
  • Table 31: CERC-007, Product Description
  • Table 32: Tadekinig Alfa, Product Description
  • Table 33: Tadekinig Alfa, Clinical Trial Description, 2020
  • Table 34: Market Size of Adult-onset Still's Disease (AOSD) in 7MM in USD Million (2017-2030)
  • Table 35: The US Market Size of Adult-onset Still's Disease (AOSD) in USD Million (2017-2030)
  • Table 36: US Market Size of Adult-onset Still's Disease (AOSD) in USD Million (2017-2030)
  • Table 37: Market Size of Adult-onset Still's Disease (AOSD) in Germany, USD Millions (2017-2030)
  • Table 38: Germany Market Size of Adult-onset Still's Disease (AOSD) by Therapies in USD Million (2017-2030)
  • Table 39: Market Size of Adult-onset Still's Disease (AOSD) associated in France, USD Millions (2017-2030)
  • Table 40: France Market Size of Adult-onset Still's Disease (AOSD) by Therapies in USD Million (2017-2030)
  • Table 41: Market Size of Adult-onset Still's Disease (AOSD) in Italy, USD Millions (2017-2030)
  • Table 42: Italy Market Size of Adult-onset Still's Disease (AOSD) by Therapies in USD Million (2017-2030)
  • Table 43: Market Size of Adult-onset Still's Disease (AOSD) in Spain, USD Millions (2017-2030)
  • Table 44: Spain Market Size of Adult-onset Still's Disease (AOSD) by Therapies in USD Million (2017-2030)
  • Table 45: Market Size of Adult-onset Still's Disease (AOSD) in the UK, USD Millions (2017-2030)
  • Table 46: UK Market Size of Adult-onset Still's Disease (AOSD) by Therapies in USD Million (2017-2030)
  • Table 47: Market Size of Adult-onset Still's Disease (AOSD) in Japan, USD Millions (2017-2030)
  • Table 48: Japan Market Size of Adult-onset Still's Disease (AOSD) by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: Pathogenesis
  • Figure 2: Total Prevalent Cases of Adult-onset Still's Disease (AOSD) in 7MM (2017-2030)
  • Figure 3: Total Prevalent Cases of AOSD in the United States (2017-2030)
  • Figure 4: Gender-Specific cases of Adult-onset Still's Disease (AOSD) in the US (2017-2030)
  • Figure 5: Complications Associated with Adult-onset Still's Disease (AOSD) in the US (2017-2030)
  • Figure 6: Total Prevalent cases of Adult-onset Still's Disease (AOSD) in Germany (2017-2030)
  • Figure 7: Gender-specific cases of Adult-onset Still's Disease (AOSD) in Germany (2017-2030)
  • Figure 8: Complications Associated with Adult-onset Still's Disease (AOSD) in Germany (2017-2030)
  • Figure 9: Total Prevalent cases of Adult-onset Still's Disease (AOSD) in France (2017-2030)
  • Figure 10: Gender-specific cases of Adult-onset Still's Disease (AOSD) in France (2017-2030)
  • Figure 11: Complications Associated with Adult-onset Still's Disease (AOSD) in France (2017-2030)
  • Figure 12: Total Prevalent cases of Adult-onset Still's Disease (AOSD) in Italy (2017-2030)
  • Figure 13: Gender-specific cases of Adult-onset Still's Disease (AOSD) in Italy (2017-2030)
  • Figure 14: Complications Associated with Adult-onset Still's Disease (AOSD) in Italy (2017-2030)
  • Figure 15: Total Prevalent cases of Adult-onset Still's Disease (AOSD) in Spain (2017-2030)
  • Figure 16: Gender-specific cases of Adult-onset Still's Disease (AOSD) in Spain (2017-2030)
  • Figure 17: Complications Associated with Adult-onset Still's Disease (AOSD) in Spain (2017-2030)
  • Figure 18: Total Prevalent cases of Adult-onset Still's Disease (AOSD) in the UK (2017-2030)
  • Figure 19: Gender-specific cases of Adult-onset Still's Disease (AOSD) in the UK (2017-2030)
  • Figure 20: Complications Associated with Adult-onset Still's Disease (AOSD) in the UK (2017-2030)
  • Figure 21: Total Prevalent cases of Adult-onset Still's Disease (AOSD) in Japan (2017-2030)
  • Figure 22: Gender-specific cases of Adult-onset Still's Disease (AOSD) in Japan (2017-2030)
  • Figure 23: Complications Associated with Adult-onset Still's Disease (AOSD) in Japan (2017-2030)
  • Figure 24: Treatment Algorithm of Adult-onset Still's Disease
  • Figure 25: Unmet Needs of Adult-onset Still's Disease
  • Figure 26: Market Size of Adult-onset Still's Disease (AOSD) in USD Million (2017-2030)
  • Figure 27: Market Size of Adult-onset Still's Disease (AOSD) in the US, USD Millions (2017-2030)
  • Figure 28: Market Size of Adult-onset Still's Disease (AOSD) in the US by therapies, USD Millions (2017-2030)
  • Figure 29: Market Size of Adult-onset Still's Disease (AOSD) in Germany, USD Millions (2017-2030)
  • Figure 30: Market Size of Adult-onset Still's Disease (AOSD) in Germany by therapies, USD Millions (2017-2030)
  • Figure 31: Market Size of Adult-onset Still's Disease (AOSD) in France, USD Millions (2017-2030)
  • Figure 32: Market Size of Adult-onset Still's Disease (AOSD) in France by therapies, USD Millions (2017-2030)
  • Figure 33: Market Size of Adult-onset Still's Disease (AOSD) in Italy, USD Millions (2017-2030)
  • Figure 34: Market Size of Adult-onset Still's Disease (AOSD) in Italy by therapies, USD Millions (2017-2030)
  • Figure 35: Market Size of Adult-onset Still's Disease (AOSD) in Spain, USD Millions (2017-2030)
  • Figure 36: Market Size of Adult-onset Still's Disease (AOSD) in Spain by therapies, USD Millions (2017-2030)
  • Figure 37: Market Size of Adult-onset Still's Disease (AOSD) in the UK, USD Millions (2017-2030)
  • Figure 38: Market Size of Adult-onset Still's Disease (AOSD) in the UK by therapies, USD Millions (2017-2030)
  • Figure 39: Market Size of Adult-onset Still's Disease (AOSD) in Japan, USD Millions (2017-2030)
  • Figure 40: Market Size of Adult-onset Still's Disease (AOSD) in Japan by therapies, USD Millions (2017-2030)
  • Figure 41: Market Drivers
  • Figure 42: Market Barriers